Research trials often employ a once-weekly subcutaneous micro-dosing approach, typically around 0.1 mL, to maintain consistent exposure levels in peptide models
The August 15 order sets a clear evidentiary standard, requiring testing through scintigraphy, breath tests, or wireless motility capsules
Restaurant dining presents unique challenges
The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough
Food remaining in the stomach for extended periods creates more opportunities for reflux into the oesophagus, causing the burning sensation characteristic of heartburn
DuBrock HM, AbouEzzeddine OF, Redfield MM (2018) High-sensitivity C-reactive protein in heart failure with preserved ejection fraction
